Palantir Technologies' rich valuation is justified, and any long-term holders can still benefit from outsized returns. Click ...

UnitedHealth's shares drop 40% in 2025 amid challenges, with mixed Q1 earnings and margin pressures ahead. Read why I rate ...

JBS offers a 15% combined yield, strong growth potential, and US listing benefits. See here to know why it's rated a Buy for ...

Elon Musk oversees Tesla's US & Europe sales after exec departure, reshaping leadership amid sales slumps and declining ...

The Australian manufacturing sector is contracting further, as evidenced by the Ai Group Industry Index falling to ...

ServiceNow excels as a B2B software provider and has steadily grown revenues over the past decade. Find out why NOW stock is ...

Yext's bottom line is improving, but organic growth remains challenged. Click here to see why YEXT stock is a Hold.

British American Tobacco remains attractively valued with a low P/E ratio and a robust dividend yield, providing a margin of ...

Kura Oncology's ziftomenib shows promise in AML treatment, with FDA Priority Review ahead. Read here for an analysis of KURA ...

Invesco Mortgage Capital is facing challenges with capital allocation and shareholder value. See why we have downgraded IVR ...

Whitecap Resources' acquisition of Veren enhances diversification, synergies, and efficiency. Read here for more analysis of ...

Healthcare Realty offers a 7-8% yield but faces rate pressures and tight dividend coverage. Learn why stabilization and ...